| 39949-3 |
Views multiple areas^W In-111 Satumomab IV |
Find |
XXX |
Pt |
Doc |
NM |
|
ACTIVE |
NM Unspecified body region Multiple area Views W In-111 Satumomab IV |
|
MAJ |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
RAD |
|
39949-3 |
|
NM |
|
|
Both |
|
|
|
0 |
NM Vs Mult areas W In-111 Satmb IV |
|
|
|
N |
|
111 In; 111In; Document; Films; Finding; Findings; Imaging; Indium 111; Misc; Miscellaneous; Mult; Multi; OncoScint; Other; Point in time; Rad; RADIOLOGY; Random; Scan; Spec; To be specified in another part of the message; Unspecified; View; Vs Mult areas; VWS; W In-111 Satmb IV |
2.64 |
2.15 |
|
|
|
|
|
|
|
|
|
|
The scale has been changed from "Nar" to "Doc" to fit with the CDA model.; Method of "Radnuc" was changed to "NM". The LOINC/RadLex Committee agreed to use a subset of the two-letter DICOM modality codes as the primary modality identifier.; Updated System from "^Patient" to "XXX" based on the LOINC/RadLex unified model. |
0 |
| 3995-8 |
Propylhexedrine |
MCnc |
Bld |
Pt |
Qn |
|
|
ACTIVE |
Propylhexedrine [Mass/volume] in Blood |
|
MIN |
DefinitionDescription |
|
|
ug/mL |
|
|
|
|
|
|
DRUG/TOX |
|
3995-8 |
|
|
|
|
Both |
|
|
|
0 |
Propylhexedrine Bld-mCnc |
|
|
|
Y |
|
Addiction; Benzedrex; Blood; Dristan; DRUG/TOXICOLOGY; Drugs; Drugs of abuse; Hexahydrodesoxyephedrine; Illicit; Level; Mass concentration; Obesin; Point in time; PotentialForAbuse; QNT; Quan; Quant; Quantitative; Random; WB; Whole blood |
2.42 |
1 |
|
|
|
|
|
|
|
ug/mL |
|
|
|
0 |
| 39950-1 |
Views multiple areas^W Tc-99m capromab pendatide IV |
Find |
Pelvis>Prostate |
Pt |
Doc |
NM |
|
ACTIVE |
NM Prostate Multiple area Views W Tc-99m capromab pendatide IV |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
RAD |
|
39950-1 |
|
NM |
|
|
Both |
|
|
|
0 |
NM Prostate Vs Mult areas W Tc99mPMSA IV |
|
|
|
N |
|
99 mTC; 99mTc; Document; Films; Finding; Findings; Imaging; Mult; Multi; Pelvic; Point in time; Prost; Prostatic; Prostatscint; Rad; RADIOLOGY; Random; Scan; TC-99CM; Tc99m; TC-99M; Technetium 99m; View; Vs Mult areas; VWS; W Tc99mPMSA IV |
2.64 |
2.15 |
|
|
|
|
|
|
|
|
|
|
The scale has been changed from "Nar" to "Doc" to fit with the CDA model.; Method of "Radnuc" was changed to "NM". The LOINC/RadLex Committee agreed to use a subset of the two-letter DICOM modality codes as the primary modality identifier.; Changed System from "Prostate" to "Pelvis>Prostate" for conformance with the LOINC/Radlex unified model. |
0 |
| 39951-9 |
Views for tumor multiple areas^W Tc-99m Sestamibi IV |
Find |
XXX |
Pt |
Doc |
NM |
|
ACTIVE |
NM Unspecified body region Views for tumor multiple areas W Tc-99m Sestamibi IV |
|
MAJ |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
RAD |
|
39951-9 |
|
NM |
|
|
Both |
|
|
|
0 |
NM Vs Mult area for tumor W Tc99mMIBI IV |
|
|
|
N |
|
99 mTC; 99mTc; Cardiolite; Document; Films; Finding; Findings; Imaging; MIBI; Misc; Miscellaneous; Mult; Multi; Other; Point in time; Rad; RADIOLOGY; Random; Scan; Spec; TC-99CM; Tc99m; TC-99M; Tc99mMIBI; Technetium 99m; To be specified in another part of the message; Unspecified; View; Vs for tumor Mult areas; VWS; W Tc99mMIBI IV |
2.64 |
2.15 |
|
|
|
|
|
|
|
|
|
|
The scale has been changed from "Nar" to "Doc" to fit with the CDA model.; Method of "Radnuc" was changed to "NM". The LOINC/RadLex Committee agreed to use a subset of the two-letter DICOM modality codes as the primary modality identifier.; Updated System from "^Patient" to "XXX" based on the LOINC/RadLex unified model. |
0 |
| 39952-7 |
Views for blood flow+function^W radionuclide IV |
Find |
Pelvis>Scrotum+Testicle |
Pt |
Doc |
NM |
|
ACTIVE |
NM Scrotum and testicle Views for blood flow and function |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
RAD |
|
39952-7 |
|
NM |
|
|
Both |
|
|
|
0 |
NM Scrotum+Test Vs bld flow+fn W RNC IV |
|
|
|
N |
|
Bld flow; Document; Dynamic; FCN; Films; Finding; Findings; Func; Funct; Imaging; Pelvic; Point in time; Rad; RADIOLOGY; Random; RN; RNC; Scan; Scrotal; Scrotal Contents; Testicular; Testies; Testis; View; Vs bld flow; Vs bld flow+fn; VWS; W RNC IV |
2.64 |
2.15 |
|
|
|
|
|
|
|
|
|
|
The scale has been changed from "Nar" to "Doc" to fit with the CDA model.; Method of "Radnuc" was changed to "NM". The LOINC/RadLex Committee agreed to use a subset of the two-letter DICOM modality codes as the primary modality identifier. Changed Core Component from "Views static & flow" to "Views for blood flow+function".; Added "Pelvis" as region imaged per LOINC/RadLex unified model |
0 |
| 39953-5 |
Guidance for localization of tumor multiple areas^W radionuclide IV |
Find |
XXX |
Pt |
Doc |
NM |
|
ACTIVE |
NM Guidance for localization of tumor multiple areas of Unspecified body region |
|
MAJ |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
RAD |
|
39953-5 |
|
NM |
|
|
Both |
|
|
|
0 |
NM Guided Tum loc Mult areas--W RNC IV |
|
|
|
N |
|
CorePlaybook; Document; Finding; Findings; Guid; Guide; Guided; Imaging; Local; Misc; Miscellaneous; Mult; Multi; Other; Playbook; Point in time; Rad; RADIOLOGY; Random; RN; RNC; Scan; Spec; To be specified in another part of the message; Tum loc; Tum loc Mult areas; Unspecified; W RNC IV |
2.64 |
2.15 |
|
|
|
|
|
|
|
|
|
|
The scale has been changed from "Nar" to "Doc" to fit with the CDA model.; Method of "Radnuc" was changed to "NM". The LOINC/RadLex Committee agreed to use a subset of the two-letter DICOM modality codes as the primary modality identifier.; Updated System from "^Patient" to "XXX" based on the LOINC/RadLex unified model. |
0 |
| 39954-3 |
Views for thrombosis^W radionuclide IV |
Find |
XXX>Vein |
Pt |
Doc |
NM |
|
ACTIVE |
NM Vein Views for thrombosis |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
RAD |
|
39954-3 |
|
NM |
|
|
Both |
|
|
|
0 |
NM Vein Vs for thrombosis W RNC IV |
|
|
|
N |
|
Cardio; Cardiology; Document; Films; Finding; Findings; Heart Disease; Imaging; Misc; Miscellaneous; Other; Point in time; Rad; Radiology; Random; RN; RNC; Scan; Spec; To be specified in another part of the message; Unspecified; Ven; Venogram; Venous; View; Vs for thrombosis; VWS; W RNC IV |
2.64 |
2.15 |
|
|
|
|
|
|
|
|
|
|
The scale has been changed from "Nar" to "Doc" to fit with the CDA model.; Method of "Radnuc" was changed to "NM". The LOINC/RadLex Committee agreed to use a subset of the two-letter DICOM modality codes as the primary modality identifier.; Added "XXX" as unspecified region imaged per LOINC/RadLex unified model |
0 |
| 39955-0 |
Creatinine^pre XXX challenge |
MCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Creatinine [Mass/volume] in Serum or Plasma --pre XXX challenge |
|
MIN |
DefinitionDescription |
|
|
mg/dL |
|
|
|
|
|
|
CHAL |
|
39955-0 |
|
|
|
|
Observation |
|
|
|
0 |
Creat pre chal SerPl-mCnc |
|
|
|
N |
|
Before; CHEMISTRY.CHALLENGE TESTING; CR; Crea; Creat; Level; Mass concentration; Pl; Plasma; Plsm; Point in time; pre chal; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.73 |
2.15 |
|
|
|
|
|
|
|
mg/dL |
|
|
|
0 |
| 39956-8 |
Creatinine^1.5H pre XXX challenge |
MCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Creatinine [Mass/volume] in Serum or Plasma --1.5 hours pre XXX challenge |
|
MIN |
DefinitionDescription |
|
|
mg/dL |
|
|
|
|
|
|
CHAL |
|
39956-8 |
|
|
|
|
Observation |
|
|
|
0 |
Creat 1.5h pre chal SerPl-mCnc |
|
|
|
N |
|
1 1/2 hours; 1 1/2 HR; 1.5h pre chal; 1.5Hr; 90 min; 90 minutes; 90M; 90min; Before; CHEMISTRY.CHALLENGE TESTING; CR; Crea; Creat; Level; Mass concentration; Pl; Plasma; Plsm; Point in time; pre chal; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.7 |
2.15 |
|
|
|
|
|
|
|
mg/dL |
|
|
|
0 |
| 39957-6 |
Creatinine^1H pre XXX challenge |
MCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Creatinine [Mass/volume] in Serum or Plasma --1 hour pre XXX challenge |
|
MIN |
DefinitionDescription |
|
|
mg/dL |
|
|
|
|
|
|
CHAL |
|
39957-6 |
|
|
|
|
Observation |
|
|
|
0 |
Creat 1h pre chal SerPl-mCnc |
|
|
|
N |
|
1 hour; 1.0Hr; 1h pre chal; 60 min; 60 minutes; 60M; 60min; Before; CHEMISTRY.CHALLENGE TESTING; CR; Crea; Creat; Level; Mass concentration; Pl; Plasma; Plsm; Point in time; pre chal; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.7 |
2.15 |
|
|
|
|
|
|
|
mg/dL |
|
|
|
0 |
| 39958-4 |
Creatinine^45M pre XXX challenge |
MCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Creatinine [Mass/volume] in Serum or Plasma --45 minutes pre XXX challenge |
|
MIN |
DefinitionDescription |
|
|
mg/dL |
|
|
|
|
|
|
CHAL |
|
39958-4 |
|
|
|
|
Observation |
|
|
|
0 |
Creat 45M pre chal SerPl-mCnc |
|
|
|
N |
|
45M pre chal; Before; CHEMISTRY.CHALLENGE TESTING; CR; Crea; Creat; Level; Mass concentration; Pl; Plasma; Plsm; Point in time; pre chal; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.7 |
2.15 |
|
|
|
|
|
|
|
mg/dL |
|
|
|
0 |
| 39959-2 |
Creatinine^30M pre XXX challenge |
MCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Creatinine [Mass/volume] in Serum or Plasma --30 minutes pre XXX challenge |
|
MIN |
DefinitionDescription |
|
|
mg/dL |
|
|
|
|
|
|
CHAL |
|
39959-2 |
|
|
|
|
Observation |
|
|
|
0 |
Creat 30M pre chal SerPl-mCnc |
|
|
|
N |
|
30M pre chal; Before; CHEMISTRY.CHALLENGE TESTING; CR; Crea; Creat; Level; Mass concentration; Pl; Plasma; Plsm; Point in time; pre chal; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.7 |
2.15 |
|
|
|
|
|
|
|
mg/dL |
|
|
|
0 |
| 3996-6 |
Propylhexedrine |
PrThr |
Urine |
Pt |
Ord |
|
|
ACTIVE |
Propylhexedrine [Presence] in Urine |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DRUG/TOX |
|
3996-6 |
|
|
|
|
Both |
|
|
|
0 |
Propylhexedrine Ur Ql |
|
|
|
|
|
Addiction; Benzedrex; Dristan; DRUG/TOXICOLOGY; Drugs; Drugs of abuse; Hexahydrodesoxyephedrine; Illicit; Obesin; Ordinal; Point in time; PotentialForAbuse; PR; QL; Qual; Qualitative; Random; Screen; UA; UR; Urn |
2.56 |
1 |
|
|
|
|
|
|
|
|
|
|
The Property has been changed from ACnc to reflect the new model for ordinal terms where results are based on a cut-off value.; The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 39960-0 |
Creatinine^45M post XXX challenge |
MCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Creatinine [Mass/volume] in Serum or Plasma --45 minutes post XXX challenge |
|
MIN |
DefinitionDescription |
|
|
mg/dL |
|
|
|
|
|
|
CHAL |
|
39960-0 |
|
|
|
|
Observation |
|
|
|
0 |
Creat 45M p chal SerPl-mCnc |
|
|
|
N |
|
45M p chal; After; CHEMISTRY.CHALLENGE TESTING; CR; Crea; Creat; Level; Mass concentration; p chal; Pl; Plasma; Plsm; Point in time; PST; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.7 |
2.15 |
|
|
|
|
|
|
|
mg/dL |
|
|
|
0 |
| 39961-8 |
Creatinine^3.5H post XXX challenge |
MCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Creatinine [Mass/volume] in Serum or Plasma --3.5 hours post XXX challenge |
|
MIN |
DefinitionDescription |
|
|
mg/dL |
|
|
|
|
|
|
CHAL |
|
39961-8 |
|
|
|
|
Observation |
|
|
|
0 |
Creat 3.5h p chal SerPl-mCnc |
|
|
|
N |
|
3.5h p chal; After; CHEMISTRY.CHALLENGE TESTING; CR; Crea; Creat; Level; Mass concentration; p chal; Pl; Plasma; Plsm; Point in time; PST; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.7 |
2.15 |
|
|
|
|
|
|
|
mg/dL |
|
|
|
0 |
| 39962-6 |
Creatinine^3.75H post XXX challenge |
MCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Creatinine [Mass/volume] in Serum or Plasma --3.75 hours post XXX challenge |
|
MIN |
DefinitionDescription |
|
|
mg/dL |
|
|
|
|
|
|
CHAL |
|
39962-6 |
|
|
|
|
Observation |
|
|
|
0 |
Creat 3.75h p chal SerPl-mCnc |
|
|
|
N |
|
3.75h p chal; After; CHEMISTRY.CHALLENGE TESTING; CR; Crea; Creat; Level; Mass concentration; p chal; Pl; Plasma; Plsm; Point in time; PST; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.7 |
2.15 |
|
|
|
|
|
|
|
mg/dL |
|
|
|
0 |
| 39963-4 |
Creatinine^4H post XXX challenge |
MCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Creatinine [Mass/volume] in Serum or Plasma --4 hours post XXX challenge |
|
MIN |
DefinitionDescription |
|
|
mg/dL |
|
|
|
|
|
|
CHAL |
|
39963-4 |
|
|
|
|
Observation |
|
|
|
0 |
Creat 4h p chal SerPl-mCnc |
|
|
|
N |
|
4h p chal; After; CHEMISTRY.CHALLENGE TESTING; CR; Crea; Creat; Level; Mass concentration; p chal; Pl; Plasma; Plsm; Point in time; PST; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.7 |
2.15 |
|
|
|
|
|
|
|
mg/dL |
|
|
|
0 |
| 39964-2 |
Creatinine^4.5H post XXX challenge |
MCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Creatinine [Mass/volume] in Serum or Plasma --4.5 hours post XXX challenge |
|
MIN |
DefinitionDescription |
|
|
mg/dL |
|
|
|
|
|
|
CHAL |
|
39964-2 |
|
|
|
|
Observation |
|
|
|
0 |
Creat 4.5h p chal SerPl-mCnc |
|
|
|
N |
|
270 min; 4 1/2 hours; 4.5h p chal; After; CHEMISTRY.CHALLENGE TESTING; CR; Crea; Creat; Level; Mass concentration; p chal; Pl; Plasma; Plsm; Point in time; PST; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.7 |
2.15 |
|
|
|
|
|
|
|
mg/dL |
|
|
|
0 |
| 39965-9 |
Creatinine^5.25H post XXX challenge |
MCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Creatinine [Mass/volume] in Serum or Plasma --5.25 hours post XXX challenge |
|
MIN |
DefinitionDescription |
|
|
mg/dL |
|
|
|
|
|
|
CHAL |
|
39965-9 |
|
|
|
|
Observation |
|
|
|
0 |
Creat 5.25h p chal SerPl-mCnc |
|
|
|
N |
|
5.25h p chal; After; CHEMISTRY.CHALLENGE TESTING; CR; Crea; Creat; Level; Mass concentration; p chal; Pl; Plasma; Plsm; Point in time; PST; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.7 |
2.15 |
|
|
|
|
|
|
|
mg/dL |
|
|
|
0 |
| 39966-7 |
Creatinine^5.5H post XXX challenge |
MCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Creatinine [Mass/volume] in Serum or Plasma --5.5 hours post XXX challenge |
|
MIN |
DefinitionDescription |
|
|
mg/dL |
|
|
|
|
|
|
CHAL |
|
39966-7 |
|
|
|
|
Observation |
|
|
|
0 |
Creat 5.5h p chal SerPl-mCnc |
|
|
|
N |
|
5.5h p chal; After; CHEMISTRY.CHALLENGE TESTING; CR; Crea; Creat; Level; Mass concentration; p chal; Pl; Plasma; Plsm; Point in time; PST; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.7 |
2.15 |
|
|
|
|
|
|
|
mg/dL |
|
|
|
0 |
| 39967-5 |
Creatinine^6.5H post XXX challenge |
MCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Creatinine [Mass/volume] in Serum or Plasma --6.5 hours post XXX challenge |
|
MIN |
DefinitionDescription |
|
|
mg/dL |
|
|
|
|
|
|
CHAL |
|
39967-5 |
|
|
|
|
Observation |
|
|
|
0 |
Creat 6.5h p chal SerPl-mCnc |
|
|
|
N |
|
6.5h p chal; After; CHEMISTRY.CHALLENGE TESTING; CR; Crea; Creat; Level; Mass concentration; p chal; Pl; Plasma; Plsm; Point in time; PST; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.7 |
2.15 |
|
|
|
|
|
|
|
mg/dL |
|
|
|
0 |
| 39968-3 |
Creatinine^8H post XXX challenge |
MCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Creatinine [Mass/volume] in Serum or Plasma --8 hours post XXX challenge |
|
MIN |
DefinitionDescription |
|
|
mg/dL |
|
|
|
|
|
|
CHAL |
|
39968-3 |
|
|
|
|
Observation |
|
|
|
0 |
Creat 8h p chal SerPl-mCnc |
|
|
|
N |
|
8h p chal; After; CHEMISTRY.CHALLENGE TESTING; CR; Crea; Creat; Level; Mass concentration; p chal; Pl; Plasma; Plsm; Point in time; PST; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.7 |
2.15 |
|
|
|
|
|
|
|
mg/dL |
|
|
|
0 |
| 39969-1 |
Creatinine^9H post XXX challenge |
MCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Creatinine [Mass/volume] in Serum or Plasma --9 hours post XXX challenge |
|
MIN |
DefinitionDescription |
|
|
mg/dL |
|
|
|
|
|
|
CHAL |
|
39969-1 |
|
|
|
|
Observation |
|
|
|
0 |
Creat 9h p chal SerPl-mCnc |
|
|
|
N |
|
9h p chal; After; CHEMISTRY.CHALLENGE TESTING; CR; Crea; Creat; Level; Mass concentration; p chal; Pl; Plasma; Plsm; Point in time; PST; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.7 |
2.15 |
|
|
|
|
|
|
|
mg/dL |
|
|
|
0 |
| 3997-4 |
Propylhexedrine |
MCnc |
Urine |
Pt |
Qn |
|
|
ACTIVE |
Propylhexedrine [Mass/volume] in Urine |
|
MIN |
DefinitionDescription |
|
|
ug/mL |
|
|
|
|
|
|
DRUG/TOX |
|
3997-4 |
|
|
|
|
Both |
|
|
|
0 |
Propylhexedrine Ur-mCnc |
|
|
|
Y |
|
Addiction; Benzedrex; Dristan; DRUG/TOXICOLOGY; Drugs; Drugs of abuse; Hexahydrodesoxyephedrine; Illicit; Level; Mass concentration; Obesin; Point in time; PotentialForAbuse; QNT; Quan; Quant; Quantitative; Random; UA; UR; Urn |
2.42 |
1 |
|
|
|
|
|
|
|
ug/mL |
|
|
|
0 |
| 39970-9 |
Creatinine^10H post XXX challenge |
MCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Creatinine [Mass/volume] in Serum or Plasma --10 hours post XXX challenge |
|
MIN |
DefinitionDescription |
|
|
mg/dL |
|
|
|
|
|
|
CHAL |
|
39970-9 |
|
|
|
|
Observation |
|
|
|
0 |
Creat 10h p chal SerPl-mCnc |
|
|
|
N |
|
10h p chal; After; CHEMISTRY.CHALLENGE TESTING; CR; Crea; Creat; Level; Mass concentration; p chal; Pl; Plasma; Plsm; Point in time; PST; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.7 |
2.15 |
|
|
|
|
|
|
|
mg/dL |
|
|
|
0 |
